GR3003895T3 - - Google Patents

Info

Publication number
GR3003895T3
GR3003895T3 GR910402106T GR910402106T GR3003895T3 GR 3003895 T3 GR3003895 T3 GR 3003895T3 GR 910402106 T GR910402106 T GR 910402106T GR 910402106 T GR910402106 T GR 910402106T GR 3003895 T3 GR3003895 T3 GR 3003895T3
Authority
GR
Greece
Prior art keywords
halogen
substituted
phosphono group
atoms
lower alkyl
Prior art date
Application number
GR910402106T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4280350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3003895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3003895T3 publication Critical patent/GR3003895T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Control Of El Displays (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Glass Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
GR910402106T 1986-11-21 1992-02-27 GR3003895T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466686 1986-11-21

Publications (1)

Publication Number Publication Date
GR3003895T3 true GR3003895T3 (el) 1993-03-16

Family

ID=4280350

Family Applications (1)

Application Number Title Priority Date Filing Date
GR910402106T GR3003895T3 (el) 1986-11-21 1992-02-27

Country Status (27)

Country Link
US (1) US4939130A (el)
EP (1) EP0275821B1 (el)
JP (1) JP2744238B2 (el)
KR (1) KR960010752B1 (el)
AT (1) ATE72816T1 (el)
AU (1) AU607722B2 (el)
CA (1) CA1338937C (el)
CY (1) CY1827A (el)
DD (1) DD270533A5 (el)
DE (2) DE3776880D1 (el)
DK (1) DK174098B1 (el)
ES (1) ES2038692T4 (el)
FI (1) FI87570C (el)
GR (1) GR3003895T3 (el)
HK (1) HK114894A (el)
HU (1) HU199150B (el)
IE (1) IE59816B1 (el)
IL (1) IL84497A (el)
LU (1) LU90838I2 (el)
MX (1) MX9427A (el)
NL (1) NL300058I2 (el)
NO (2) NO173446C (el)
NZ (1) NZ222610A (el)
PH (1) PH24345A (el)
PT (1) PT86167B (el)
SG (1) SG92194G (el)
ZA (1) ZA878698B (el)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
CA2107082A1 (en) * 1991-04-27 1992-10-28 Ichiro Mori Triazole compounds
RU2126414C1 (ru) * 1992-05-29 1999-02-20 Дзе Проктер энд Гэмбл Фармасьютикалз, Инк. Содержащие четвертичный азот фосфонаты для лечения анормального кальциевого и фосфатного метаболизма, а также профилактики и лечения зубных налетов и зубных камней, фармацевтические композиции и способ лечения
SK144694A3 (en) * 1992-05-29 1995-06-07 Procter & Gamble Pharma Thio-substituted nitrogen containing heterocyclic phosphate compounds for treating calcium and phosphate metabolism
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
NZ253524A (en) * 1992-05-29 1997-01-29 Procter & Gamble Pharma Sulphur-containing phosphonate derivatives and medicaments (for treating abnormal calcium and phosphate metabolism)
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5753634A (en) * 1992-05-29 1998-05-19 The Procter & Gamble Company Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism
AU675796B2 (en) * 1992-06-30 1997-02-20 Procter & Gamble Pharmaceuticals, Inc. Compositions for the treatment of arthritis containing phosphonates and NSAIDS
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5880111A (en) * 1995-06-07 1999-03-09 Farcasiu; Dan Therapeutic derivations of diphosphonates
IL115041A0 (en) * 1995-08-23 1995-12-08 Yissum Res Dev Co Novel bisphosphonates process for their preparation and pharmaceutical compositions containing them
EP0854724B1 (en) * 1995-09-29 2005-03-16 Novartis AG Method of treating the navicular disease in horses
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP0970095B1 (en) * 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
RU2273642C2 (ru) * 1999-12-22 2006-04-10 Метабэйсис Терапьютикс, Инк. Бисамидатные фосфонатные соединения, являющиеся ингибиторами фруктозо-1,6-бисфосфатазы
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
SI1591122T1 (sl) 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
CN1272013C (zh) * 2000-06-20 2006-08-30 诺瓦提斯公司 二膦酸盐在制备用于治疗骨更新异常增加的病症的药物中的应用
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
SK14042003A3 (sk) 2001-05-16 2004-05-04 Novartis Ag Kombinácia N-{5-[4-metylpiperazinometyl)benzoylamido]-2- metylfenyl}-4-(3-pyridyl)-2-pyrimidínamínu chemoterapeutického činidla a farmaceutický prostriedok, ktorý ju obsahuje
AU2003250190A1 (en) * 2002-07-30 2004-02-23 Novartis Ag Combination of an aromatase inhibitor with a bisphosphonate
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
ES2376425T3 (es) * 2002-09-16 2012-03-13 Novartis Ag �?cido zoledrónico para prevenir o reducir fracturas secundarias tras fractura de cadera.
DE60315514T3 (de) * 2002-12-20 2012-04-26 F. Hoffmann-La Roche Ag Hochdosierte ibandronat-formulierung
EP1525207A2 (en) * 2003-02-27 2005-04-27 Teva Pharmaceutical Industries Limited Process for purification of zoledronic acid
WO2005005447A2 (en) * 2003-07-03 2005-01-20 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US20050049693A1 (en) * 2003-08-25 2005-03-03 Medtronic Vascular Inc. Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
RU2326695C2 (ru) * 2003-09-19 2008-06-20 Пфайзер Продактс Инк. Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната
WO2005041899A2 (en) * 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
ATE508134T1 (de) * 2003-12-23 2011-05-15 Alchymars S P A Amorphe form das natriumsalzes der ibandronsäure
WO2005063717A1 (en) * 2003-12-26 2005-07-14 Natco Pharma Limited An improved process for the preparation of zoledronic acid
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
EP1827606A2 (en) * 2004-12-06 2007-09-05 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
WO2006062072A1 (ja) * 2004-12-10 2006-06-15 Tmrc Co., Ltd. 転移癌治療剤および癌転移抑制剤
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100687A1 (en) * 2005-03-24 2006-09-28 Dabur Pharma Ltd. Disodium pamidronate aqueous formulation
EP1891081B1 (en) * 2005-06-13 2014-08-20 Jubilant Organosys Limited Process for producing bisphosphonic acids and forms thereof
AR054673A1 (es) 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
WO2007032808A1 (en) * 2005-09-12 2007-03-22 Dr. Reddy's Laboratories Ltd. Crystalline trihydrate of zoledronic acid
AU2007209961A1 (en) * 2006-01-27 2007-08-09 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
JP2009526073A (ja) * 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
JP2009530414A (ja) * 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
WO2007125521A2 (en) * 2006-05-02 2007-11-08 Ranbaxy Laboratories Limited Polymorphic form of zoledronic acid and processes for their preparation
EP2099741A2 (en) * 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
EP2097397A1 (en) * 2006-11-21 2009-09-09 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
AU2007323557A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
US20090082312A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched zoledronic acid
ITPA20070034A1 (it) * 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
MX2010005786A (es) 2007-11-30 2010-06-09 Novartis Ag Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol.
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20110034418A1 (en) * 2008-04-04 2011-02-10 Karen Beltz Pharmaceutical composition with bisphosphonate
PL213599B1 (pl) * 2008-10-31 2013-03-29 Politechnika Gdanska Sposób otrzymywania kwasu [1-hydroksy-2-(1H-imidazol-1-ilo)-etylideno] bisfosfonowego
US20100130746A1 (en) * 2008-11-26 2010-05-27 Martin Kas Process for Making Zoledronic Acid
EP2192126B1 (en) 2008-11-26 2013-03-27 Synthon B.V. Process for making zoledronic acid
WO2010076258A1 (en) * 2008-12-23 2010-07-08 Novartis Ag Phenylalkyl-imidazole-bisphosphonate compounds
WO2011014781A1 (en) 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9867838B2 (en) 2009-09-01 2018-01-16 Duke University Methods for treating heart failure using bisphosphonate compositions
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
RU2012148716A (ru) 2010-04-16 2014-05-27 Новартис Аг Способы и композиции для улучшения оссеоинтеграции имплантата
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
HU230718B1 (hu) 2011-02-08 2017-11-28 Richter Gedeon Nyrt. Új eljárás dronsavak gyógyszeripari előállítására
CN102276650A (zh) * 2011-06-22 2011-12-14 苏州莱克施德药业有限公司 一种唑来膦酸的制备方法
US9949992B2 (en) 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
CN102617642B (zh) * 2012-02-24 2015-11-18 江苏省原子医学研究所 一种含2-乙基咪唑的双膦酸化合物及其制备方法和应用
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9012432B2 (en) 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
EP3737676B1 (en) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
RU2725962C2 (ru) * 2020-02-12 2020-07-07 Акционерное Общество "Фарм-Синтез" Способ приготовления фармацевтической композиции на основе золедроновой кислоты в виде раствора для инфузий для лечения онкологических заболеваний и способ получения фармацевтической композиции на основе золедроновой кислоты в виде концентрата для приготовления раствора для инфузий для лечения онкологических заболеваний
CN114057648B (zh) * 2020-07-30 2024-02-20 常州方圆制药有限公司 一种唑来膦酸中间体杂质的制备方法
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3203308A1 (de) * 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate
DE3203307A1 (de) * 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Phosphonate, und diese enthaltende pharmazeutische verbindungen
EP0084822B1 (de) * 1982-01-27 1986-01-08 Schering Aktiengesellschaft Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
NL300058I1 (nl) 2001-12-01
EP0275821A1 (de) 1988-07-27
FI87570B (fi) 1992-10-15
DK174098B1 (da) 2002-06-17
NZ222610A (en) 1990-09-26
IL84497A (en) 1994-10-21
AU607722B2 (en) 1991-03-14
NO874856L (no) 1988-05-24
NO173446C (no) 1993-12-15
KR880006204A (ko) 1988-07-22
PH24345A (en) 1990-06-13
HK114894A (en) 1994-10-27
MX9427A (es) 1993-12-01
IL84497A0 (en) 1988-04-29
HU199150B (en) 1990-01-29
DD270533A5 (de) 1989-08-02
DE3776880D1 (de) 1992-04-02
PT86167B (pt) 1990-08-31
CA1338937C (en) 1997-02-25
ZA878698B (en) 1988-05-23
NL300058I2 (nl) 2002-02-01
FI87570C (fi) 1993-01-25
JPS63150291A (ja) 1988-06-22
LU90838I2 (fr) 2001-11-19
DE10199052I1 (de) 2002-01-10
FI875096A0 (fi) 1987-11-18
HUT46330A (en) 1988-10-28
ES2038692T3 (es) 1993-08-01
CY1827A (en) 1995-12-01
NO173446B (no) 1993-09-06
PT86167A (en) 1987-12-01
KR960010752B1 (ko) 1996-08-08
NO874856D0 (no) 1987-11-20
SG92194G (en) 1995-04-28
EP0275821B1 (de) 1992-02-26
IE59816B1 (en) 1994-04-06
JP2744238B2 (ja) 1998-04-28
ES2038692T4 (es) 2012-02-10
ATE72816T1 (de) 1992-03-15
IE873148L (en) 1988-05-21
DK609587A (da) 1988-05-22
NO2001015I2 (no) 2004-10-11
US4939130A (en) 1990-07-03
AU8145387A (en) 1988-05-26
DK609587D0 (da) 1987-11-20
FI875096A (fi) 1988-05-22

Similar Documents

Publication Publication Date Title
GR3003895T3 (el)
EP0320118A3 (en) Peptides with collagenase inhibiting activity
DE3363593D1 (en) 2-nitro-ethene diamines, process for their preparation and their use as medicines
LTIP704A (en) Process for the preparation of hexahydroazepines derivatives
MY103191A (en) Novel substituted aminomethanediphosphonic acids
AU9035491A (en) Chiral hydantoin resolution
SE8400451D0 (sv) Bronchodilatory azepino /1,2-a/pyrimidine derivatives and acid addition salts thereof and pharmaceutical compositions containig same